Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Primary thrombocythaemia: diagnosis and management.

T C Pearson1

  • 1Division of Haematology, United Medical School, Guy's Hospital, London.

British Journal of Haematology
|June 1, 1991
PubMed
Summary

Differentiating essential thrombocythemia (ET) from reactive thrombocytosis is crucial due to ET's higher risk of blood clots. Early treatment to control platelet production is recommended for all ET patients to prevent complications.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Belatacept Combined With Transient Calcineurin Inhibitor Therapy Prevents Rejection and Promotes Improved Long-Term Renal Allograft Function.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

Fc-Silent Anti-CD154 Domain Antibody Effectively Prevents Nonhuman Primate Renal Allograft Rejection.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2017
Same author

The Management of Polycythaemia Vera.

Hematology (Amsterdam, Netherlands)·2016
Same author

The Management of Essential Thrombocythaemia.

Hematology (Amsterdam, Netherlands)·2016
Same author

Renal transplantation using belatacept without maintenance steroids or calcineurin inhibitors.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2014
Same author

Racial disparities in kidney graft survival: does donor quality explain the difference?

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2012

Area of Science:

  • Hematology
  • Oncology
  • Internal Medicine

Background:

  • Essential thrombocythemia (ET) poses a higher risk of thromboembolic events compared to reactive thrombocytosis, necessitating accurate differential diagnosis.
  • Understanding the complications and diagnostic challenges associated with ET is vital for effective patient management.

Purpose of the Study:

  • To highlight the importance of differentiating essential thrombocythemia from reactive thrombocytosis.
  • To discuss current and potential future diagnostic methods for ET.
  • To outline recommended treatment strategies for ET, including acute and long-term management.

Main Methods:

  • Review of clinical and laboratory criteria for diagnosing essential thrombocythemia.
  • Discussion of the potential role of molecular biology in future diagnostics.
  • Analysis of treatment approaches for managing thrombocytosis, hemorrhage, and occlusive events in ET patients.

Main Results:

  • A combination of clinical and laboratory findings is currently the most effective diagnostic approach for ET.
  • Treatment aimed at suppressing megakaryocytic proliferation is advised for all ET patients to mitigate complications and potential myelofibrotic transition.
  • Specific therapeutic recommendations include platelet transfusions for hemorrhage and aspirin for vascular occlusive lesions, alongside hydroxyurea or busulfan based on age.

Conclusions:

  • Accurate diagnosis of essential thrombocythemia is critical due to its thrombotic risks.
  • Prompt treatment to control platelet counts is essential for preventing major complications in ET patients.
  • Age-specific long-term therapies, including busulfan and hydroxyurea, are recommended, with interferon-alpha showing potential for specific patient groups.

Related Experiment Videos